NEW YORK--Zeneca Pharmaceuticals' Casodex, an oral antiandrogen
agent, has received approval for marketing in the United Kingdom
for the treatment of advanced prostate cancer. Zeneca has also
filed for approval of Casodex in the United States and several
other countries, Zeneca president Robert C. Black said at a media
Other new anticancer agents from Zeneca in clinical development
include Tomudex, a cytotoxic thymidylate synthase inhibitor for
colorectal cancer, and Arimidex, an oral nonsteroidal aromatase
inhibitor for breast cancer.
The company's LHRH agonist analog Zoladex (goserelin acetate),
currently marketed as a 3.6 mg implant for prostate cancer, has
been recommended for a new indication--palliation of advanced
breast cancer . An NDA has also been filed for a 10.8-mg, 3-month
depo formulation, Mr. Black said.